In a pivotal move for the biotechnology sector, Charles River Laboratories International, Inc. (NYSE: CRL) announced on July 13, 2026, a strategic collaboration with Arovella Therapeutics Ltd (ASX: ALA) to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services. This partnership aims to enhance the development of Arovella's novel Invariant Natural Killer T (iNKT) cell therapy platform, a promising approach for treating various forms of cancer.

2. Accelerating Development with NGS Services

The collaboration will leverage Charles River's advanced NGS services to facilitate cell characterization, a crucial step in the manufacturing process of Arovella's lead product, ALA-101. Following a successful Investigational New Drug (IND) application, the U.S. Food and Drug Administration (FDA) has approved the use of NGS for viral safety testing of two cell banks integral to the manufacturing of ALA-101. This approval signifies a major milestone in the development of safer and more efficient cell and gene therapies.

Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing at Charles River, expressed enthusiasm about the collaboration, stating, “Providing Arovella with NGS services as they advance a transformative iNKT cell therapy platform for patients with lymphoma and leukemia closely aligns with our strategic goal to deliver enhanced client experiences.” Dolph further emphasized the importance of modern, GMP-ready sequencing in the development of these therapies.

3. Comprehensive Testing Services

In addition to NGS services for cell bank characterization, Charles River will conduct viral safety release testing on clinical batches of ALA-101. This next-generation, off-the-shelf CAR-iNKT cell therapy focuses on treating CD19+ B cell lymphomas and leukemias. Dr. Nicole van der Weerden, CEO of Arovella Therapeutics, highlighted the collaboration's significance by stating, "We are thrilled to collaborate with Charles River Laboratories to strengthen the foundation of our clinical manufacturing program." She noted that the integration of NGS and validated viral safety tests reinforces their commitment to safety, quality, and regulatory rigor.

4. The Role of Next Generation Sequencing

Next Generation Sequencing is revolutionizing therapeutic development with its ability to characterize and test advanced therapies efficiently. NGS not only enhances genetic analysis but also improves pathogen detection through its high throughput, scalability, and speed. Charles River’s CGMP NGS testing services ensure compliance with regulatory requirements, including those set by the GMP, FDA, EMA, and ICH Q5A and Q5B, thus accelerating development timelines while maintaining safety standards.

The recent acquisition of Pathoquest, a leader in NGS solutions, further amplifies Charles River's capabilities, allowing for even faster and more advanced sequencing-based testing across the development pipeline.

5. A Robust Biologics Testing Offering

Charles River's extensive experience in cell banking and characterization complements its full range of CGMP-compliant cell bank production and storage services. The company boasts nine CGMP-compliant ISO cleanroom suites and a rapid 8-10 week timeline for cell bank completion to release. With over 2,000 cell and viral banks produced, Charles River supports client programs from research and development through to commercial manufacturing.

6. About Arovella Therapeutics

Arovella Therapeutics Ltd is a biotechnology firm dedicated to developing its iNKT cell therapy platform, derived from Imperial College London, to target blood cancers and solid tumors. The cornerstone of their therapeutic pipeline is ALA-101, which utilizes CAR19-iNKT cells engineered to target the CD19 antigen prevalent in many cancer types. Arovella is also expanding its focus to include solid tumor treatments utilizing its licensed CLDN18.2-targeting technology.

7. About Charles River Laboratories

Charles River Laboratories provides critical products and services that empower pharmaceutical and biotechnology companies, government agencies, and academic institutions to accelerate research and drug development. With a dedicated team committed to enhancing the discovery and safe manufacturing of new therapies, Charles River continues to play a vital role in advancing healthcare solutions worldwide.

As the collaboration between Charles River and Arovella Therapeutics unfolds, it holds the potential to significantly impact the landscape of cancer treatment, offering hope to patients through innovative therapeutic approaches.

Original press release